前列腺癌
恩扎鲁胺
雄激素受体
医学
LNCaP公司
癌症研究
前列腺
生物标志物
下调和上调
免疫组织化学
肿瘤科
雄激素剥夺疗法
内科学
细胞生长
癌症
细胞
PTEN公司
队列
雄激素
前列腺切除术
细胞周期
临床试验
受体
抗雄激素
作者
Steven M. Blinka,Sonali Arora,Dmytro Rudoy,Anika Gowda,Peter Yong,Yisoo Hwang,Michael D. Nyquist,Ryon P. Graf,Gerald Li,Peter S. Nelson,Michael Thomas Schweizer,Andrew Caleb Hsieh
标识
DOI:10.1158/1078-0432.ccr-26-1405
摘要
PURPOSE: Treatment intensification with androgen receptor pathway inhibitors (ARPI) has become the standard of care for patients with metastatic prostate cancer (mPC). However, there remains an unmet need to identify biomarkers for treatment resistance. In this study, we identify SPEN inactivation as a driver of ARPI resistance. EXPERIMENTAL DESIGN: Preclinical studies were performed using LNCaP and VCaP cell lines. Data from a nationwide prostate cancer clinicogenomic database were extracted. The log-rank test and Cox proportional hazards models were used to compare time to next treatment (TTNT) on ARPIs with or without SPEN mutations. SPEN immunohistochemistry was performed on a rapid-autopsy metastatic tissue microarray. RESULTS: SPEN was identified as a top enzalutamide resistance hit in an unbiased genome-wide loss-of-function screen. SPEN inactivation results in upregulation of cell-cycle proliferation and basal/stem cell activity, as well as increased translation of prooncogenic genes. In a large patient cohort (N = 6,828), SPEN mutations are enriched following treatment with ARPIs (2.1%-3.6%; P = 0.001) and correlate with shorter TTNT on ARPIs in patients with metastatic hormone-sensitive prostate cancer (6.4 vs. 29.7 months; HR, 2.67; P = 0.02). In a metastatic rapid-autopsy cohort (N = 181), low SPEN H-score is associated with shorter time on abiraterone (5 vs. 7.9 months; P = 0.023) in metastatic castration-resistant prostate cancer. CONCLUSIONS: In real-world cohorts, loss of SPEN function across genomic, transcriptomic, and protein levels is associated with reduced benefit from ARPI therapy in mPC. These findings identify SPEN inactivation as a clinically relevant biomarker of ARPI resistance that warrants prospective evaluation to guide treatment selection.
科研通智能强力驱动
Strongly Powered by AbleSci AI